stars 1 stars 2 stars 3

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), is a clinical-stage biopharmaceutical company that is focused on developing novel treatments where there is significant unmet clinical need or where no current therapies are available, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke.

DiaMedica Therapeutics Inc. Questions

The DiaMedica Therapeutics Inc. annual revenue was $22.4 million in 2026.

Rick Pauls is the President and CEO of DiaMedica Therapeutics Inc..

31 people are employed at DiaMedica Therapeutics Inc..

DiaMedica Therapeutics Inc. is based in Minneapolis, Minnesota.

The NAICS codes for DiaMedica Therapeutics Inc. are [325, 32, 541714, 5417, 54171, 54, 541].

The SIC codes for DiaMedica Therapeutics Inc. are [283, 2833, 28, 2835].

Top DiaMedica Therapeutics Inc. Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users